Somewhat Favorable News Coverage Somewhat Unlikely to Impact Nabriva Therapeutics AG (NBRV) Share Price
News headlines about Nabriva Therapeutics AG (NASDAQ:NBRV) have been trending somewhat positive on Tuesday, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Nabriva Therapeutics AG earned a news impact score of 0.22 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 47.8848696788652 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the news headlines that may have impacted Accern’s analysis:
- Q3 2017 Earnings Estimate for Nabriva Therapeutics AG (NASDAQ:NBRV) Issued By Wedbush (americanbankingnews.com)
- Cantor Fitzgerald Comments on Nabriva Therapeutics AG’s FY2017 Earnings (NASDAQ:NBRV) (americanbankingnews.com)
- Nabriva Therapeutics AG (NASDAQ:NBRV) Major Shareholder Sells $186,795.00 in Stock (americanbankingnews.com)
- Nabriva Therapeutics AG (NASDAQ:NBRV) Major Shareholder Hbm Healthcare Investments (Ca Sells 19,803 Shares (americanbankingnews.com)
- Q3 2017 Earnings Estimate for Nabriva Therapeutics AG Issued By Leerink Swann (NASDAQ:NBRV) (americanbankingnews.com)
Nabriva Therapeutics AG (NASDAQ:NBRV) opened at 9.60 on Tuesday. The company has a 50-day moving average price of $10.38 and a 200 day moving average price of $10.39. The firm’s market capitalization is $257.64 million. Nabriva Therapeutics AG has a 1-year low of $3.52 and a 1-year high of $12.75.
Nabriva Therapeutics AG (NASDAQ:NBRV) last issued its earnings results on Monday, August 7th. The biotechnology company reported ($0.54) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($5.83) by $5.29. The business had revenue of $1.05 million during the quarter, compared to analyst estimates of $1.34 million. Equities analysts anticipate that Nabriva Therapeutics AG will post ($2.43) earnings per share for the current year.
Several research firms recently commented on NBRV. Zacks Investment Research upgraded Nabriva Therapeutics AG from a “hold” rating to a “buy” rating and set a $12.00 target price for the company in a research note on Thursday, August 10th. HC Wainwright reiterated a “buy” rating on shares of Nabriva Therapeutics AG in a research note on Friday, May 12th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Nabriva Therapeutics AG in a research note on Friday, June 23rd. ValuEngine lowered Nabriva Therapeutics AG from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Finally, Wedbush reiterated an “outperform” rating and issued a $13.00 target price on shares of Nabriva Therapeutics AG in a research note on Monday, May 15th. One research analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $15.43.
In related news, Director George Harrison Talbot sold 325 shares of Nabriva Therapeutics AG stock in a transaction on Thursday, May 25th. The stock was sold at an average price of $100.56, for a total transaction of $32,682.00. Following the completion of the sale, the director now owns 3,854 shares of the company’s stock, valued at $387,558.24. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder Hbm Healthcare Investments (Ca sold 8,558 shares of Nabriva Therapeutics AG stock in a transaction on Thursday, June 29th. The shares were sold at an average price of $10.96, for a total value of $93,795.68. Following the sale, the insider now directly owns 2,591,396 shares of the company’s stock, valued at approximately $28,401,700.16. The disclosure for this sale can be found here. In the last ninety days, insiders sold 242,458 shares of company stock valued at $2,621,221.
About Nabriva Therapeutics AG
Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.
Receive News & Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.